S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:MGNX

MacroGenics - MGNX Stock Forecast, Price & News

$5.22
+0.13 (+2.55%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.11
$5.41
50-Day Range
$2.25
$5.22
52-Week Range
$2.13
$28.09
Volume
1.16 million shs
Average Volume
944,785 shs
Market Capitalization
$320.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.67

MacroGenics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
200.1% Upside
$15.67 Price Target
Short Interest
Healthy
9.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.61
Upright™ Environmental Score
News Sentiment
0.57mentions of MacroGenics in the last 14 days
Based on 21 Articles This Week
Insider Trading
Acquiring Shares
$98,800 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.96) to ($2.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

155th out of 1,117 stocks

Pharmaceutical Preparations Industry

64th out of 550 stocks

MGNX stock logo

About MacroGenics (NASDAQ:MGNX) Stock

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MacroGenics Trading Up 3.7 %

Shares of MacroGenics stock traded up $0.19 during trading on Friday, reaching $5.28. The company's stock had a trading volume of 20,763 shares, compared to its average volume of 1,105,559. The stock has a 50-day moving average price of $3.42 and a two-hundred day moving average price of $6.54. MacroGenics has a one year low of $2.13 and a one year high of $28.09. The stock has a market capitalization of $324.51 million, a P/E ratio of -1.43 and a beta of 2.08.

Wall Street Analyst Weigh In

MGNX has been the topic of a number of research analyst reports. Guggenheim downgraded shares of MacroGenics from a "buy" rating to a "neutral" rating in a research note on Wednesday, May 4th. BTIG Research set a $6.00 target price on shares of MacroGenics in a research report on Tuesday, July 19th. Sumitomo Mitsui Financial Group lowered shares of MacroGenics from an "outperform" rating to a "neutral" rating and set a $5.00 price objective for the company. in a research report on Monday, July 18th. HC Wainwright decreased their target price on shares of MacroGenics from $41.00 to $35.00 in a report on Wednesday, May 4th. Finally, JMP Securities reduced their price target on shares of MacroGenics from $24.00 to $20.00 and set a "market outperform" rating for the company in a research report on Tuesday, July 12th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $15.67.

Insider Transactions at MacroGenics

In other news, CFO James Karrels purchased 40,000 shares of MacroGenics stock in a transaction on Wednesday, June 15th. The stock was purchased at an average price of $2.47 per share, with a total value of $98,800.00. Following the transaction, the chief financial officer now directly owns 191,776 shares in the company, valued at approximately $473,686.72. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 7.90% of the company's stock.

Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Stock News Headlines

Macrogenics: Q2 Earnings Insights - Benzinga
MacroGenics (MGNX) Q2 2022 Earnings Call Transcript
MacroGenics: Q2 Earnings Snapshot - Greenwich Time
Analyst Ratings for Macrogenics
Analysts Cuts Price Target On MacroGenics - Read Why
See More Headlines
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Company Calendar

Last Earnings
11/02/2021
Today
8/12/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGNX
Employees
427
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.67
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+200.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-202,120,000.00
Net Margins
-326.76%
Pretax Margin
-326.76%

Debt

Sales & Book Value

Annual Sales
$77.45 million
Book Value
$2.32 per share

Miscellaneous

Free Float
56,604,000
Market Cap
$320.82 million
Optionable
Optionable
Beta
2.08

Key Executives

  • Dr. Scott Koenig M.D. (Age 70)
    Ph.D., Pres, CEO & Director
    Comp: $954.14k
  • Mr. James Karrels (Age 55)
    Sr. VP, CFO & Corp. Sec.
    Comp: $577.9k
  • Mr. Eric Blasius Risser (Age 49)
    Chief Operating Officer
    Comp: $571.98k
  • Dr. Ezio Bonvini (Age 68)
    Sr. VP of Research & Chief Scientific Officer
    Comp: $612.21k
  • Dr. Thomas M. Spitznagel Ph.D. (Age 55)
    Sr. VP of Technical Operations
    Comp: $550.97k
  • Dr. Christopher Shayne James M.D.
    VP of Investor Relations & Corp. Communications
  • Mr. Jeffrey Stuart Peters (Age 50)
    Sr. VP & Gen. Counsel
  • Dr. Stephen L. Eck M.D. (Age 67)
    Ph.D., Sr. VP of Clinical Devel. & Chief Medical Officer
  • Ms. Lynn Cilinski (Age 64)
    VP, Controller & Treasurer













MGNX Stock - Frequently Asked Questions

Should I buy or sell MacroGenics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MGNX shares.
View MGNX analyst ratings
or view top-rated stocks.

What is MacroGenics' stock price forecast for 2022?

8 equities research analysts have issued 12-month price targets for MacroGenics' shares. Their MGNX share price forecasts range from $4.00 to $35.00. On average, they predict the company's share price to reach $15.67 in the next year. This suggests a possible upside of 195.0% from the stock's current price.
View analysts price targets for MGNX
or view top-rated stocks among Wall Street analysts.

How have MGNX shares performed in 2022?

MacroGenics' stock was trading at $16.05 at the beginning of the year. Since then, MGNX shares have decreased by 66.9% and is now trading at $5.31.
View the best growth stocks for 2022 here
.

When is MacroGenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our MGNX earnings forecast
.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) announced its quarterly earnings data on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.23. The biopharmaceutical company earned $15.66 million during the quarter, compared to the consensus estimate of $39.56 million. MacroGenics had a negative net margin of 326.76% and a negative trailing twelve-month return on equity of 102.68%. During the same quarter in the prior year, the firm earned ($0.66) EPS.

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.

What other stocks do shareholders of MacroGenics own?

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (2.94%), Bank of Montreal Can (1.12%), Walleye Capital LLC (0.94%), JPMorgan Chase & Co. (0.65%), FMR LLC (0.65%) and Pinnacle Associates Ltd. (0.64%). Insiders that own company stock include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends
.

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $5.31.

How much money does MacroGenics make?

MacroGenics (NASDAQ:MGNX) has a market capitalization of $326.35 million and generates $77.45 million in revenue each year. The biopharmaceutical company earns $-202,120,000.00 in net income (profit) each year or ($3.56) on an earnings per share basis.

How many employees does MacroGenics have?

The company employs 427 workers across the globe.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The official website for the company is www.macrogenics.com. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at info@macrogenics.com, or via fax at 301-251-5321.

This page (NASDAQ:MGNX) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.